Using hydrophilic Methocel® K4M, the current study sought to design a sustained-releasing and acting formulation of Domperidone, an antiemetic medication used to treat nausea and vomiting, with a typical dosage that is administered twice or three times per day. The sustained-release formulation was made using various ratios of K4M, and its quality and stability were assessed. The optimized formulation was chosen for dissolution studies and similarity profiles after pre-compression and post-compression features were analyzed. Studies on drug dissolution showed that a tablet containing CF2 had the best release profile for once-daily use. The preparation of long-acting domperidone matrices was accompanied by the display of favorable characteristics necessary for the perfect once-daily formulation. The creation of a gel layer followed by gel erosion may be the mechanism, providing a lengthy, slow-releasing pattern and a desired therapeutic effect. The idea of controlled-release formulations benefits patients and carers by decreasing the frequency of doses and the likelihood of missing doses or an overnight interval between doses.
